Skip to main content
Log in

Tissue plasminogen activator, plasminogen activator inhibitor-1 and von willebrand factor in rheumatoid arthritis

Clinical Rheumatology Aims and scope Submit manuscript

Summary

Tissue plasminogen activator (tPA), plasminogen activator inhibitor-1 (PAI-1) and von Willebrand factor (vWF), all of endothelial origin and active in the haemostasis, were analysed in 74 patients with rheumatoid arthritis. The concentrations were related to extra-articular disease and to the incidence of thromboembolic events (TE) registered in a 2-year follow-up period. Patients with extra-articular disease had a significant increase in PAI-1 activity and reduced tPA release in the venous occlusion test. von Willebrand factor, PAI-1 and also haptoglobin and triglycerides were significantly increased in the group of patients who later suffered from TE. In a multiple regression model, in which cholesterol, triglycerides and lipoprotein (a) showed significant association with TE, vWF had the strongest additive explanatory value. No distinct acute phase pattern of PAI-1 was found in any patient subgroup.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. Bachmann, F. Fibrinolysis. In: Thrombosis and Haemostasis 1987. Eds.: Verstraete, M., Vermylen, J., Lijnen, H.R., Arnout, J., Leuven University Press Leuven, 1987, 227–265.

    Google Scholar 

  2. Rijken, D.C., Wijngards, G., Welbergen, J. Relationship between tissue plasminogen activator and the activators in blood and vascular wall. Thromb Res 1980, 18, 815–830.

    Article  PubMed  Google Scholar 

  3. Dosne, A.M., Dupuy, E., Bedevin, E. Production of a fibrinolytic inhibitor by cultured endothelial cells derived from human umbilical vein. Thromb Res 1978, 12, 377–387.

    Article  PubMed  Google Scholar 

  4. Jaffe, E.A., Hoyer, L.W., Nachman, R.L. Synthesis of von Willebrand factor by cultured human endothelial cells. Proc Natl Acad Sci 1974, 71, 1906–1909.

    PubMed  Google Scholar 

  5. Hart, D.A., Fritzler, M.J. Regulation of plasminogen activators and their inhibitors in rheumatic diseases: New understanding and the potential for new directions. J Rheumatol 1989, 16, 1184–1191.

    PubMed  Google Scholar 

  6. Jordan, J.M., Bates Allen, N., Pizzo S.V. Defective release of tissue plasminogen activator in systemic and cutaneous vasculitis. Am J Med 1987, 82, 397–400.

    Article  PubMed  Google Scholar 

  7. Belch, J.J.F., Mc Ardle, B., Madhok, R., McLaughlin, K., Capell, H.A., Forbes, C.D., Sturrock, R.D. Decreased plasma fibrinolysis in patients with rheumatoid arthritis. Ann Rheum Dis 1984, 43, 774–777.

    PubMed  Google Scholar 

  8. van de Putte, L.B.A., Noordhoek Hegt, V., Overbeek, T.A. Activators and inhibitors of fibrinolysis in rheumatoid and nonrheumatoid synovial membranes. Arthritis Rheum 1977, 20, 671–678.

    PubMed  Google Scholar 

  9. Kikuchi, H., Tanaka, S., Matsuo, O. Plasminogen activators in synovial fluid from patients with rheumatoid arthritis. J Rheumatol 1987, 14, 439–445.

    PubMed  Google Scholar 

  10. Mussoni, L., Pintucci, G., Romano, G., De Benedetti, F., Massa, M., Martini, A. Decreased fibrinolytic activity in juvenile chronic arthritis. Ann Rheum Dis 1990, 49, 973–975.

    PubMed  Google Scholar 

  11. Belch, J.J.F., Zoma, A.A., Richards, I.M., McLaughlin, K., Forbes, C.D., Sturrock, R.D. Vascular damage and factor VIII related antigen in the rheumatic diseases. Rheumatol Im 1987, 7; 107–111.

    Article  Google Scholar 

  12. Nusinow, S.R., Federici, A.B., Zimmerman, T.S., Curd, J.G. Increased von Willebrand factor antigen in the plasma of patients with vasculitis. Arthritis Rheum 1984, 27, 1405–1410.

    PubMed  Google Scholar 

  13. Bleil, L., Manger, B., Winkler, T.H., Herrman, M., Burmester, G.R., Krapf, F.E., Kalden, J.R. The role of antineutrophil cytoplasm antibodies, anticardiolipin antibodies, von Willebrand factor antigen, and fibronectin for the diagnosis of systemic vasculitis. J Rheumatol 1991, 18, 1199–1206.

    PubMed  Google Scholar 

  14. Jansson, J.H. The fibrinolytic system in ischaemic heart disease. In: Nilsson, T.K., Boman, K., Jansson, J.H., Clinical Aspects on Fibrinolysis. Ed.: Almqvist & Wiksell International, Stockholm 1991, 95–110.

    Google Scholar 

  15. Hamsten, A., Wiman, B., De Faire, U., Blombäck, M. Increased plasma levels of a rapid inhibitor of tissue plasminogen activator in young survivors of myocardial infarction. N Engl J Med 1985, 313, 1557–1563.

    PubMed  Google Scholar 

  16. Nilsson, I.M., Ljungnér, H., Tengborn, L. Two different mechanisms in patients with venous thrombosis and defective fibrinolysis: low concentrations of plasminogen activator or increased concentration of plasminogen activator inhibitor. Br Med J 1985, 290, 1453–1456.

    Google Scholar 

  17. Wahlberg, T., Blombäck, M., Övermark, I. Blood coagulation studies in 45 patients with ischemic cerebrovascular disease and 44 patients with venous thromboembolic disease. Acta Med Scand 1980, 207, 385–390.

    PubMed  Google Scholar 

  18. Schmitz-Huebner, U., Thompson, S.G., Balleisen, L., Fechtrup, C., Grosse-Heitmeyer, W., Kirchhof, B., Most, E., Müller, U.S., Seiffert, C., Seiffert, D., van de Loo, J. Lack of association between haemostatic variables and the presence or extent of coronary atherosclerosis. Br Heart J 1988, 59, 287–291.

    PubMed  Google Scholar 

  19. Hamsten, A., Walldius, G., Szamosi, A., Blombäck, M., de Faire, U., Dahlén, G., Landou, C., Wiman, B. Plasminogen activator inhibitor in plasma: risk factor for recurrent myocardial infarction. Lancet 1987, ii, 3–8.

    Article  Google Scholar 

  20. Jansson, J.H., Nilsson, T.K., Olofsson, B.O. Tissue plasminogen activator and other risk factors as predictors of cardiovascular events in patients with severe angina pectoris. Eur Heart J 1991, 12, 157–161.

    PubMed  Google Scholar 

  21. Jansson, J.H., Nilsson, T.K., Johnson, O. von Willebrand factor in plasma: a novel risk factor for recurrent myocardial infarction and death. Br Heart J 1991, 66, 351–355.

    PubMed  Google Scholar 

  22. Isomäki, H.A., Mutru, O., Koota, K. Death rate and causes of death in patients with rheumatoid arthritis. Scand J Rheumatol 1975, 4, 205–208.

    PubMed  Google Scholar 

  23. Allebeck, P., Ahlbom, A., Allander, E. Increased mortality among patients with rheumatoid arthritis, but where RA does not appear on death certificate. Scand J Rheumatol 1981, 10, 301–306.

    PubMed  Google Scholar 

  24. Reilly, P.A., Cosh, J.A., Maddison, P.J., Rasker, J.J., Silman, A.J. Mortality and survival in rheumatoid arthritis: a 25-year prospective study of 100 patients. Ann Rheum Dis 1990, 49, 363–369.

    PubMed  Google Scholar 

  25. Rantapää-Dahlqvist, S., Wållberg-Jonsson, S., Dahlén, G.H. Lipoprotein (a), lipids and lipoproteins in patients with rheumatoid arthritis. Ann Rheum Dis 1991, 50, 366–368.

    PubMed  Google Scholar 

  26. Ropes, M.W., Bennett, G.A., Cobb, S. Diagnostic criteria for rheumatoid arthritis. Ann Rheum Dis 1959, 18, 49–53.

    PubMed  Google Scholar 

  27. Cooperating Clinics Committee of the American Rheumatism Association: A seven day variability study of 499 patients with peripheral rheumatoid arthritis. Arthritis Rheum 1965, 8, 302–334.

    Google Scholar 

  28. Dahlén, G.H. Lipoprotein (a) in relation to atherosclerotic diseases. In: Prog Clin Biol Res. Eds.: Widhalm, K., Naito, H.K., 1988, 255, 27–36.

    PubMed  Google Scholar 

  29. Wiman, B., Mellbring, G., Rånby, M. Plasminogen activator release during venous stasis and exercise as determined by a new specific assay. Clin Chem Acta 1983, 127, 279–288.

    Google Scholar 

  30. Eriksson, E., Rånby, M., Gyzander, E., Risberg, B. Determination of plasminogen activator inhibitor in plasma using tPA and a chromogenic single-point poly-D-lysine stimulated assay. Thromb Res 1988, 50, 91–101.

    Article  PubMed  Google Scholar 

  31. Cejka, J. Enzyme immunoassay for factor VIII-related antigen. Clin Chem 1982, 28, 1356–1358.

    PubMed  Google Scholar 

  32. Rånby, M., Sundell, I.B., Johnson, O., Ledin, M-C, Dahlén G. Activity of plasminogen activator inhibitor-1 (PAI-1) in a population of northern Sweden. Fibrinolysis 1990, 2, 54–55.

    Article  Google Scholar 

  33. Lau, C.S., McLaren, M., Hanslip, J., Morley, K.D., Belch, J.J.F. Abnormal fibrinolytic response in patients with rheumatoid arthritis complicated by vasculitis. Br J Rheum 1991, Abstracts suppl: 68.

  34. Angles-Cano, E., Sultan, Y., Cluvel, J.P. Predisposing factors to thrombosis in systemic lupus erythematosus. J Lab Clin Med 1979, 94, 313–323.

    Google Scholar 

  35. Nilsson, T.K., Norberg, B., Wållberg-Jonsson, S., Rantapää-Dahlqvist, S. von Willebrand factor in plasma as risk factor for cardiovascular events. J Int Med 1991, 229, 557–558.

    Google Scholar 

  36. Juhan-Vague, I., Alessi, M.C., Vague, P. Increased plasma plasminogen activator inhibitor 1 levels. A possible link between insulin resistance and atherothrombosis. Diabetologia 1991, 34, 457–462.

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Rights and permissions

Reprints and permissions

About this article

Cite this article

Wållberg-Jonsson, S., Dahlén, G.H., Nilsson, T.K. et al. Tissue plasminogen activator, plasminogen activator inhibitor-1 and von willebrand factor in rheumatoid arthritis. Clin Rheumatol 12, 318–324 (1993). https://doi.org/10.1007/BF02231572

Download citation

  • Received:

  • Accepted:

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF02231572

Key words

Navigation